Clinical characteristics of carbapenem-resistant Klebsiella pneumoniae infections in ill and colonized children in Colombia

Pediatric Infectious Disease Journal

Volumn 35, Issue 3, 2016, Pages 237-241

  Díaz, Alejandro ^a   Ortiz, Diana Cristina ^a   Trujillo, Mónica ^a,b,c   Garcés, Carlos ^a,d   Jaimes, Fabian ^b,d   Restrepo, Andrea Victoria ^a,b  

^a UNIVERSIDAD CES   (Colombia)

^b HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^c Clinica Universitaria Bolivariana   (Colombia)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Carbapenem resistance; Children; Colombia; Klebsiella pneumoniae; Medellin; lactamases

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; COLISTIN; MEROPENEM; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; BACTEREMIA; BACTERIAL COLONIZATION; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COLOMBIA; CONFERENCE PAPER; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY HEALTH CARE; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; HETEROZYGOTE; INFANT; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEWBORN; TERTIARY CARE CENTER;

BETA-LACTAM RESISTANCE; CARBAPENEMS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; COLOMBIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84959237657     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000987     Document Type: Conference Paper

References (62)

1. The antibiotic alarm. Nature. 2013;495:141.
2. Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62:165-170.
3. Hampton T. Report reveals scope of US antibiotic resistance threat. JAMA. 2013;310:1661-1663.
4. McKenna M. Antibiotic resistance: the last resort. Nature. 2013;499:394-396.
5. da Silva RM, Traebert J, Galato D. Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: a review of epidemiological and clinical aspects. Expert Opin Biol Ther. 2012;12:663-671.
6. Swaminathan M, Sharma S, Poliansky Blash S, et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol. 2013;34:809-817.
7. Heritage J, M'Zali FH, Gascoyne-Binzi D, et al. Evolution and spread of SHV extended-spectrum beta-lactamases in gram-negative bacteria. J Antimicrob Chemother. 1999;44:309-318.
8. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother. 2005;56:451-454.
9. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161-182, Table of Contents.
10. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-686.
11. Martínez MJ, García MI, Sánchez EG, et al. [Available carbapenems: properties and differences]. Enferm Infect Microbiol Clin. 2010;28 (Suppl 2):53-64.
12. Petrosillo N, Giannella M, Lewis R, et al. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11:159-177.
13. Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell. 2007;128:1037-1050.
14. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969-976.
15. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPCproducing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother. 2009;53:3365-3370.
16. Chen L, Mediavilla JR, Endimiani A, et al. Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants. J Clin Microbiol. 2011;49:579-585.
17. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151-1161.
18. Hidron AI, Edwards JR, Patel J, et al; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29:996-1011.
19. Maya JJ, Ruiz SJ, Blanco VM, et al. Current status of carbapenemases in Latin America. Expert Rev Anti Infect Ther. 2013;11:657-667.
20. Villegas MV, Lolans K, Correa A, et al; Colombian Nosocomial Resistance Study Group. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50:2880-2882.
21. Lopez JA, Correa A, Navon-Venezia S, et al. Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain. Clin Microbiol Infect. 2011;17:52-56.
22. Cuzon G, Naas T, Correa A, et al. Dissemination of the KPC-2 carbapenemase in non-Klebsiella pneumoniae enterobacterial isolates from Colombia. Int J Antimicrob Agents. 2013;42:59-62.
23. Pereira GH, Garcia DO, Mostardeiro M, et al. Spread of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in Sao Paulo, Brazil. J Hosp Infect. 2011;79:182-183.
24. Maltezou HC, Kontopidou F, Katerelos P, et al. Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children. Pediatr Infect Dis J. 2013;32:e151-e154.
25. Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis. 2014;58:1439-1448.
26. Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis. 2012;55:852-859.
27. Benenson S, Warburg G, Hidalgo-Grass C, et al. Comparison of two carbapenem-resistant Klebsiella pneumoniae clones: from a contained outbreak in a paediatric population and from a national epidemic. J Antimicrob Chemother. 2012;67:1651-1654.
28. Liu Y, Li XY, Wan LG, et al. Molecular characterization of the bla(KPC-2) gene in clinical isolates of carbapenem-resistant Klebsiella pneumoniae from the pediatric wards of a Chinese hospital. Can J Microbiol. 2012;58:1167-1173.
29. Drew RJ, Turton JF, Hill RL, et al. Emergence of carbapenem-resistant Enterobacteriaceae in a UK paediatric hospital. J Hosp Infect. 2013;84:300-304.
30. Dara JS, Chen L, Levi MH, et al. Microbiological and genetic characterization of carbapenem-resistant Klebsiella pneumoniae isolated from pediatric patients. J Pediatric Infect Dis Soc. 2014;3:e10-e14.
31. Dirajlal-Fargo S, De Biasi R, Campos J, et al. Carbapenem-resistant Enterobacteriaceae in pediatric patients: epidemiology and risk factors. Infect Control Hosp Epidemiol. 2014;35:447-449.
32. Montealegre MC, Correa A, Briceño DF, et al; Colombian Nosocomial Resistance Study Group. Novel VIM metallo-beta-lactamase variant, VIM- 24, from a Klebsiella pneumoniae isolate from Colombia. Antimicrob Agents Chemother. 2011;55:2428-2430.
33. Pasteran F, Albornoz E, Faccone D, et al. Emergence of NDM-1-producing Klebsiella pneumoniae in Guatemala. J Antimicrob Chemother. 2012;67:1795-1797.
34. Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B, et al. Outbreak of NDM-1-producing Klebsiella pneumoniae in a neonatal unit in Colombia. Antimicrob Agents Chemother. 2013;57:1957-1960.
35. Correa A, Restrepo A, Mazo L, et al. Control of an outbreak of carbapenem resistant Klebsiella pneumoniae in a tertiary care medical center (Colombia). In: SHEA, ed. Best practices in infection prevention and control. An international perspective. 2nd ed. United States: The Society for Healthcare Epidemiology of America; 2012:52-56.
36. Talbot TR, Bratzler DW, Carrico RM, et al; Healthcare Infection Control Practices Advisory Committee. Public reporting of health care-associated surveillance data: recommendations from the healthcare infection control practices advisory committee. Ann Intern Med. 2013;159:631-635.
37. Beekmann SE, Diekema DJ, Huskins WC, et al; Infectious Diseases Society of America Emerging Infections Network. Diagnosing and reporting of central line-associated bloodstream infections. Infect Control Hosp Epidemiol. 2012;33:875-882.
38. Al-Qas Hanna F, Sambirska O, Iyer S, et al. Clinician practice and the National Healthcare Safety Network definition for the diagnosis of catheterassociated urinary tract infection. Am J Infect Control. 2013;41:1173-1177.
39. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-332.
40. Pires J, Novais A, Peixe L. Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. J Clin Microbiol. 2013;51:4281-4283.
41. Oteo J, Hernández-Almaraz JL, Gil-Antón J, et al. Outbreak of vim-1-carbapenemase-producing Enterobacter cloacae in a pediatric intensive care unit. Pediatr Infect Dis J. 2010;29:1144-1146.
42. Marchaim D, Navon-Venezia S, Schwaber MJ, et al. Isolation of imipenemresistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother. 2008;52:1413-1418.
43. Seema K, Ranjan Sen M, Upadhyay S, et al. Dissemination of the New Delhi metallo-β-lactamase-1 (NDM-1) among Enterobacteriaceae in a tertiary referral hospital in north India. J Antimicrob Chemother. 2011;66:1646-1647.
44. Marchaim D, Chopra T, Perez F, et al. Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center. Infect Control Hosp Epidemiol. 2011;32:861-871.
45. Little ML, Qin X, Zerr DM, et al. Molecular diversity in mechanisms of carbapenem resistance in paediatric Enterobacteriaceae. Int J Antimicrob Agents. 2012;39:52-57.
46. Cendejas E, Gómez-Gil R, Gómez-Sánchez P, et al. Detection and characterization of Enterobacteriaceae producing metallo-beta-lactamases in a tertiary-care hospital in Spain. Clin Microbiol Infect. 2010;16:181-183.
47. Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 2010;31:1250-1256.
48. Gasink LB, Edelstein PH, Lautenbach E, et al. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180-1185.
49. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099-1106.
50. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798-1803.
51. Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54-60.
52. Kmeid JG, Youssef MM, Kanafani ZA, et al. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther. 2013;11:1355-1362.
53. van Duin D, Kaye KS, Neuner EA, et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75:115-120.
54. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322-2328.
55. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943-950.
56. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013;11:1333-1353.
57. Daikos GL, Markogiannakis A, Souli M, et al. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther. 2012;10:1393-1404.
58. Tamma PD, Newland JG, Pannaraj PS, et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J. 2013;32:17-22.
59. Karli A, Paksu MS, Karadag A, et al. Colistin use in pediatric intensive care unit for severe nosocomial infections: experience of an university hospital. Ann Clin Microbiol Antimicrob. 2013;12:32.
60. Celebi S, Hacimustafaoglu M, Koksal N, et al. Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. Pediatr Int. 2010;52:410-414.
61. Iosifidis E, Antachopoulos C, Ioannidou M, et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr. 2010;169:867-874.
62. Hurtado IC, Trujillo M, Restrepo A, et al. [Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae]. Rev Chilena Infectol. 2012;29:317-321.